Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapy
R. Murali, B. A. Varghese, N. Karthikeyan, A. P. T, W. S. Teo, A. McFarland, D. L. Roden, H. Holliday, C. Konrad, A. S. Cazet, E. Dodson, J. T. George, H. Levine, M. K. Jolly, A. Swarbrick, R. Nair
This paper investigates how Id1 and Id3 maintain chemoresistant CSCs in TNBC by targeting Kif11 and Aurka, and explores combination therapy to enhance tumor debulking.
bioRxiv · Sep 11, 2019 · PreprintCancer Biology